Six studies reported relapse rate (mean of 26%) and/or responder rate (mean of 28%).
This pattern is supported by evidence from secondary efficacy endpoints in RCTs (responder rate, mean number of migraine days/month, rescue medication use, migraine severity, and migraine duration).
The primary endpoint was the mean change from baseline in number of MHD in the last 28 day period (month three); secondary end points included the mean change in headache days, migraine attacks, and the 50% responder rate at month 3. Mean change in MHD (primary) was -4.2 vs. -3.0 for LY2951742 (n=107) and placebo (n=110), respectively (p = 0.003).
Thus, a high responder rate does not automatically mean a high remission rate.
A base case that is defined by the mean value of the assumed scenarios for the AVD responder rate and the first year AVD costs was simulated in order to build the basis for performing the deterministic sensitivity analyses.
Strong evidence shows that topiramate 100 or 200 mg/day is more effective than placebo in reducing mean monthly migraine frequency, and further evidence shows better effectiveness than placebo on responder rate, rescue medication use, migraine severity, and migraine duration.
Although the responder rate for these questions ranged between 39% (Eurythmy) and 72% (Oil bath/Embrocation), the mean satisfactory values ranged between 2.9 and 3.8, indicating a high level of satisfaction with the therapies.
The evidence also demonstrates a similar pattern for responder rate (the percentage of patients who experienced at least a 50% reduction in the mean frequency of migraine attacks).
However, the responder rate is relatively low.
Responder rate was statistically greater in the OG (P<0.001).
